Evidence map›Paper›PMID 31375993›Full record

Trial reportJournal of thrombosis and thrombolysis2020

Right ventricular dysfunction is superior and sufficient for risk stratification by a pulmonary embolism response team.

Yu Lin Chen, Colin Wright, Anthony P Pietropaoli, Ayman Elbadawi, Joseph Delehanty, Bryan Barrus, Igor Gosev, David Trawick, Dhwani Patel, Scott J Cameron

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. CHAClinical cardiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Acute pulmonary embolism in patients with obstructive sleep apnea: frequency, hospital outcomes, and recurrence.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yu Lin ChenDepartment of Medicine, University of Rochester, Rochester, USA. Yulin_Chen@urmc.rochester.edu.
Colin WrightDepartment of Medicine, University of Rochester, Rochester, USA.
Anthony P PietropaoliDepartment of Medicine, University of Rochester, Rochester, USA.
Ayman ElbadawiDepartment of Medicine, University of Rochester, Rochester, USA.
Joseph DelehantyDepartment of Cardiology, University of Rochester, Aab CVRI, Box CVRI, Box 601 Elmwood Ave, Rochester, NY, 14624, USA.
Bryan BarrusDepartment of Surgery, Cardiac Surgery, University of Rochester, Rochster, USA.
Igor GosevDepartment of Surgery, Cardiac Surgery, University of Rochester, Rochster, USA.
David TrawickDepartment of Medicine, University of Rochester, Rochester, USA.
Dhwani PatelDepartment of General Medicine, University of Rochester, Rochester, USA.
Scott J CameronDepartment of Medicine, University of Rochester, Rochester, USA.ORCID http://orcid.org/0000-0002-9616-1540
University of Rochester · USUniversity of Rochester Medical Center · US

Funding

Platelet ERK5 regulates myocardial infarct expansionK08HL128856 · NHLBI · UNIVERSITY OF ROCHESTER · PI CAMERON, SCOTT JAMES · 2016 to 2020
$775k
NHLBI NIH HHS 3K08HL128856NHLBI NIH HHS HL12020NHLBI NIH HHS K08 HL128856
6 · The paper itself

Abstract

Several risk stratification tools are available to predict short-term mortality in patients with acute pulmonary embolism (PE). The presence of right ventricular (RV) dysfunction is an independent predictor of mortality and may be a more efficient way to stratify risk for patients assessed by a Pulmonary Embolism Response Team (PERT). We evaluated 571 patients presenting with acute PE, then stratified them by the pulmonary embolism severity index (PESI), by the BOVA score, or categorically as low risk (no RV dysfunction by imaging), intermediate risk/submassive (RV dysfunction by imaging), or high risk/massive PE (RV dysfunction with sustained hypotension). Using imaging data to firstly define the presence of RV strain, and plasma cardiac biomarkers as additional evidence for myocardial dysfunction, we evaluated whether PESI, BOVA, or RV strain by imaging were more appropriate for determining patient risk by a PERT where rapid decision making is important. Cardiac biomarkers poorly distinguished between PESI classes and BOVA stages in patients with acute PE. Cardiac TnT and NT-proBNP easily distinguished low risk from submassive PE with an area under the curve (AUC) of 0.84 (95% CI 0.73-0.95, p < 0.0001), and 0.88 (95% CI 0.79-0.97, p < 0.0001), respectively. Cardiac TnT and NT-proBNP easily distinguished low risk from massive PE with an area under the curve (AUC) of 0.89 (95% CI 0.78-1.00, p < 0.0001), and 0.89 (95% CI 0.82-0.95, p < 0.0001), respectively. In patients with RV dysfunction, the predicted short-term mortality by PESI score or BOVA stage was lower than the observed mortality by a two-fold order of magnitude. The presence of RV dysfunction alone in the context of acute PE is sufficient for the purposes of risk stratification. More complicated risk stratification tools which require the consideration of multiple clinical variables may under-estimate short-term mortality risk.

Indexed as

Severity of Illness IndexVentricular Dysfunction, RightAgedBiomarkersFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPulmonary EmbolismRetrospective StudiesRisk AssessmentTroponin TBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)TNNT2 protein, humanTroponin TBiomarkerBOVA scorePulmonary embolism (PE)Pulmonary Embolism Response Team (PERT)Pulmonary Embolism Severity Index (PESI)Right ventricle (RV)

Identifiers

PMID31375993
PMCPMC6954969
OpenAlexW2964418257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.